Webinar: Implementing a bedaquiline-based, injectable-free regimen for drug-resistant TB
Treatment Action Group (TAG), the Global TB Community Advisory Board (TB CAB) and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) will host a webinar on 16 August 2018 at 10 am EDT / 4 pm South Africa / 5 pm Kenya on implementing a bedaquiline-based, injectable-free regimen for drug-resistant TB (DR-TB) in light of the new World Health Organization (WHO) policy brief on DR-TB regimens.
Dr. Nobert Ndjeka from the National Department
of Health in South Africa will be talking about the South
African experience as the first country to roll out this unique
and less toxic regimen and how the South Africa regimen differs
from the new WHO policy brief on DR-TB regimens (including
advantages and disadvantages).
Eunice Omesa, the Section Head for Monitoring, Evaluation & Research
from the Ministry of Health in Kenya will be talking about
practical considerations countries have in order to implement a
bedaquiline-based, injectable-free regimen bearing in mind the
new WHO policy brief on DR-TB regimens.
Perspectives
from a survivor of drug-resistant TB, and other members of civil
society will also be included. TB survivor and TB PROOF
management committee member Phumeza Tisile will
share her experience with injectable drug-induced hearing loss
and recommendations for national programs. The discussion will
be moderated by Marcus Low, Spotlight editor
and technical co-lead of the Global TB Community Advisory
Board.
Closed captioning will be available at this
link:
http://www.streamtext.net/player?event=TAG. Please rearrange your screens to view the live transcription
and the presentation.
Register now
for the August webinar to receive your log in information.
